{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:30:45Z","timestamp":1793705445085,"version":"4.5.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Identifying alternative contributors to the residual risk of atherosclerotic cardiovascular disease (ASCVD) beyond LDL cholesterol (LDL-C) levels is crucial. We investigated the relative impact of triglycerides (TGs) and high-sensitivity C-reactive protein (hs-CRP) on outcomes in statin-treated patients with well-controlled LDL-C undergoing percutaneous coronary intervention (PCI) for established ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We included 9446 statin-treated patients with LDL-C &amp;lt; 70\u2005mg\/dL undergoing PCI between 2012 and 2022, stratified into four groups: (i) no residual risk (TG &amp;lt;150\u2005mg\/dL + hs-CRP &amp;lt;2\u2005mg\/L); (ii) residual TG risk (TG \u2265150\u2005mg\/dL + hs-CRP &amp;lt;2\u2005mg\/L); (iii) residual inflammatory risk (TG &amp;lt;150\u2005mg\/dL + hs-CRP \u22652\u2005mg\/L); and (iv) residual TG and inflammatory risk (TG \u2265150\u2005mg\/dL + hs-CRP \u22652\u2005mg\/L). The primary endpoint was major adverse cardiovascular events (MACE) at 1 year, consisting of all-cause mortality, myocardial infarction, or stroke. Cox regression analysis was performed, using the no residual risk group as a reference. Of the total population, 5339 (56.5%) had no residual risk, 555 (5.9%) presented residual TG risk, 3009 (31.9%) had residual inflammatory risk, and 543 (5.7%) exhibited residual combined risk. After multivariable adjustment, patients with residual inflammatory or combined risk showed a significantly higher hazard of MACE, mainly driven by all-cause mortality. No significant difference was observed between patients with residual TG risk and those with no residual risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In statin-treated patients with well-controlled LDL-C undergoing PCI, residual inflammatory risk\u2014alone or in combination with residual TG risk\u2014was associated with a higher incidence of MACE, highlighting the need for targeted preventive strategies beyond LDL-C lowering.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf112","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:21:00Z","timestamp":1742228460000},"page":"742-751","source":"Crossref","is-referenced-by-count":28,"title":["Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease"],"prefix":"10.1093","volume":"33","author":[{"given":"Francesca Maria","family":"Di Muro","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"},{"name":"Department of Experimental and Clinical Medicine, School of Human Health Sciences, Careggi University Hospital, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-403X","authenticated-orcid":false,"given":"Birgit","family":"Vogel","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-9409","authenticated-orcid":false,"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bay","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Oliva","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Feng","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sweeny","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gitto","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Smith","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moreno","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3015-3361","authenticated-orcid":false,"given":"Johny","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasuram","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Pasquale","family":"Leone","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapoorna","family":"Kini","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin K","family":"Sharma","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , Mount Sinai Fuster Heart Hospital, 1 Gustave L. Levy Pl, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2026032619565758000_zwaf112-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026032619565758000_zwaf112-B2","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026032619565758000_zwaf112-B3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/01.CIR.0000060541.18923.E9","article-title":"Relation of inflammation and benefit of statins after percutaneous coronary interventions","volume":"107","author":"Chan","year":"2003","journal-title":"Circulation"},{"key":"2026032619565758000_zwaf112-B4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90\u2008056 participants in 14 randomised trials of statins","volume":"366","author":"Unit ES","year":"2005","journal-title":"The Lancet"},{"key":"2026032619565758000_zwaf112-B5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"2026032619565758000_zwaf112-B6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin Chem"},{"key":"2026032619565758000_zwaf112-B7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to clinic","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"2026032619565758000_zwaf112-B8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B9","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B10","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf Stefan","year":"2020","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker Paul","year":"2005","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"The Lancet"},{"key":"2026032619565758000_zwaf112-B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2026032619565758000_zwaf112-B14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"2026032619565758000_zwaf112-B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"2026032619565758000_zwaf112-B16","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2026032619565758000_zwaf112-B17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt Deepak","year":"2019","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/eurjpc\/zwae003","article-title":"Omega-3 fatty acids for cardiovascular event lowering","volume":"31","author":"Kaur","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026032619565758000_zwaf112-B20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2026032619565758000_zwaf112-B21","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026032619565758000_zwaf112-B22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026032619565758000_zwaf112-B23","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026032619565758000_zwaf112-B24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"2026032619565758000_zwaf112-B25","first-page":"939","article-title":"Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026032619565758000_zwaf112-B26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz Gregory","year":"2018","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B27","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2026032619565758000_zwaf112-B28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","article-title":"Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial","volume":"5","author":"Gencer","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026032619565758000_zwaf112-B29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA in dyslipidemias: JACC state-of-the-art review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026032619565758000_zwaf112-B30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray Kausik","year":"2020","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B31","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"2026032619565758000_zwaf112-B32","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"2026032619565758000_zwaf112-B33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.116.308834","article-title":"Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans","volume":"37","author":"Bernelot Moens","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026032619565758000_zwaf112-B34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2026032619565758000_zwaf112-B35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey Frederick","year":"2017","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B36","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"2026032619565758000_zwaf112-B37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026032619565758000_zwaf112-B38","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"2026032619565758000_zwaf112-B39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2026032619565758000_zwaf112-B40","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf112\/62493918\/zwaf112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/5\/742\/62493918\/zwaf112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/5\/742\/62493918\/zwaf112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:57:08Z","timestamp":1774569428000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/5\/742\/8088269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2026,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf112","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,3,20]]}}}